Acadia Pharmaceuticals, Inc. - Price Analysis Snapshot

This Report features up to a ten-year record of the equity Price history for Acadia Pharmaceuticals, Inc.. Tabular results include the High, Low and Closing price for the quarter. There is also a calculation of percentage change in price for both Quarterly and Annual periods. Price values are adjusted for stock splits and dividends.

Acadia Pharmaceuticals, Inc.. The Group's principal activity is to discover, develop and commercialize small molecule drugs for the treatment of central nervous system disorders.It has a product candidate in Phase II for chronic pain and a product candidate in Phase I for glaucoma both in collaboration with Allergan Inc and ACP-106 in IND-track development. The Group currently developing a portfolio consisting of four most advanced product candidates including pimavanserin, which is in Phase III development for the treatment of Parkinson's disease psychosis and retained worldwide commercialization rights to pimavanserin. It operates in the United States and Europe.

Not the Report you are looking for? Click here for more browsing options.

view sample Single Report

view sample All Basic Reports

Layout and Content of a Typical Report